Argenica Therapeutics' Neuroprotective Drug ARG-007 Shows Positive Results in Ferret Preclinical Study

A preclinical study found that Argenica Therapeutics' (ASX:AGN) ARG-007 can significantly reduce damage to brain cells, providing further evidence of the potential of the neuroprotective drug as a tre

MT NewswiresMay 14 18:54 ET

Argenica Therapeutics Price Target Cut 6.7% to A$1.40/Share by Euroz Hartleys

Argenica Therapeutics Price Target Cut 6.7% to A$1.40/Share by Euroz Hartleys

Dow JonesApr 15 21:51 ET

Argenica Therapeutics Doses First Batch of Patients for Phase Two Stroke Trial

Argenica Therapeutics (ASX:AGN) dosed the first batch of five patients for its phase two trial investigating the use of ARG-007 medication in patients with acute ischaemic stroke, according to a Wedne

MT NewswiresApr 9 22:14 ET

Argenica Therapeutics Doses First Patient in Phase Two Stroke Trial; Shares Rally 14%

Argenica Therapeutics (ASX:AGN) dosed the first patient for its phase two trial investigating the use of ARG-007 medication to treat patients with acute ischaemic stroke, according to a filing with th

MT NewswiresMar 27 20:30 ET

FDA Grants Argenica Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy Treatment; Shares Up 16%

Biotechnology company Argenica Therapeutics (ASX:AGN) has been granted the rare pediatric disease designation by the US Food and Drug Administration for its neuroprotective drug ARG-007, which is used

MT NewswiresMar 24 20:48 ET

Argenica Therapeutics Concludes Manufacturing, Release Testing for Stroke Drug; Shares Rise 3%

Argenica Therapeutics (ASX:AGN) concluded the manufacturing and release testing of GMP-grade ARG-007 drug product, intended to treat stroke patients, the biotechnology company said Monday. The ARG-007

MT NewswiresFeb 11 22:52 ET